Comment from CureDuchenne - Newport Beach, CA

Summary: CureDuchenne, an advocacy organization for Duchenne muscular dystrophy, supports the FDA's draft guidance on genome editing safety assessments but urges the agency to adopt a more flexible, risk-based approach. They argue that for severe rare diseases, the regulatory framework should prioritize timely patient access by allowing for alternative model systems and staged data generation to avoid development delays.